Refine Search

  •  
  •  
Biotech's newest task: Engineering a source of cash

...canceled plans for a 2.5-million share offering to raise $27 million in August. And Baltimore-based Osiris Therapeutics Inc., which is developing treatments to regenerate damaged bone and cartilage, canceled a $30 million offering...

http://chronicle.augusta.com/stories/1998/11/28/bus_245910.shtml
Business
1